(Q35720576)

9 August 2017

1 reference

title

Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia (English)

1 reference

9 August 2017

3

Steven A Kaplan

1 reference

9 August 2017

John S Lam

1

1 reference

9 August 2017

Kimberly L Cooper

series ordinal

2

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Medical Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

88

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

281-308

1 reference

High prevalence of benign prostatic hypertrophy in the community

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Benign prostatic hyperplasia. Medical and minimally invasive treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Management of symptomatic BPH in the US: who is treated and how?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Normal histology of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Influence of Age and Endocrine Factors on the Volume of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Comprehensive patient evaluation for benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

In vitro characterization of the alpha-adrenoceptors in human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Preclinical pharmacology of alpha1-adrenoceptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Prostatic alpha 1-adrenoceptors and uroselectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Effects of Prazosin in Patients with Benign Prostatic Obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Indoramin in the Treatment of Prostatic Bladder Outflow Obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Phytotherapy in the management of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Effects of nitric oxide on human and canine prostates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Does evaluation with the International Prostate Symptom Score predict the outcome of transurethral resection of the prostate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Long-term results following transurethral resection of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

The safety of transurethral prostatectomy: a cohort study of mortality in 9,416 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Voiding dysfunction following transurethral resection of the prostate: symptoms and urodynamic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral vaporization of the prostate: current techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral resection versus incision of the prostate: a randomized, prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Side-firing Neodymium:YAG laser prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Laser prostatectomy. Long-term follow-up of 303 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Interstitial laser therapy of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Holmium laser resection of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral microwave thermotherapy: minimally invasive therapy for benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

A 12-month study of the placebo effect in transurethral microwave thermotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Minimally invasive procedures as an alternative to medical management for lower urinary tract symptoms of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral hot water balloon thermoablation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Gonadotropins, testosterone, and the aging male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Sexual dysfunction in men with lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Sexual function in patients with LUTS suggestive of BPH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Benign prostatic hyperplasia and erectile dysfunction--is there a link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Sexual function one year after transurethral prostatic resection. Patients' own assessments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: long-term durability with Prostcare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Ejaculatory Dysfunction after Transurethral Microwave Thermotherapy for Treatment of Benign Prostatic Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

Accuracy of preoperative estimation of resection weight in transurethral prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900147-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(03)00147-0

1 reference

9 August 2017

1 reference